Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis

Table 2 Clinical response and clinical remission rates of studies included in the meta-analysis

Ref.	Group	Drug	Definition of clinical response	Clinical response rate		Definition of clinical remission	Clinical remission rate
Feagan et al[14]	Intervention 1	MLN-02	An improvement of 3 points or more on the ulcerative colitis clinical score (modification of the Mayo Clinic Scoring system)	66%	59.3%1	Ulcerative colitis clinical score of 0 or 1 and a modified Baron score of 0 or 1 with no evidence of rectal bleeding	32.2%1
	Intervention 2			53%
	Control	Placebo		33%			14.0%
Feagan et al[15]	Intervention	Vedolizumab	A reduction in the Mayo Clinic score of at least 3 points and a decrease of at least 30% from baseline, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1	47.1%		Mayo Clinic score of 2 or lower and no subscore higher than 1, and mucosal healing, defined as an endoscopic subscore of 0 or 1	16.9%
	Control	Placebo		25.5%			5.4%
Parikh et al[16]	Intervention 1	Vedolizumab	A decrease from baseline in the partial Mayo score (PMS) of ≥ 2 points and ≥ 25%, with an accompanying decrease in the subscore for rectal bleeding of ≥ 1 point or an absolute subscore for rectal bleeding of 0 or 1.	50%	56.8%1	PMS of ≤ 2 with no individual subscore > 1	58%1
	Intervention 2			63.3%
	Intervention 3			53.3%
	Control	Placebo		33.3%			50%

¹Pooled of all intervention groups. MNL-02: Vedolizumab.